On 12/26/24, Catalyst Biosciences Inc (NASDAQ: GYRE) stock enjoyed a major increase of 10.3%, closing at $13.13. Moreover, trading volume in this advance was unusually high at 162% of normal. The stock has been weak relative to the market over the last nine months but has risen 18.1% during the last week.
Current PriceTarget Research Rating
Catalyst Biosciences is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment